DMKPQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DMKPQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
DMK Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.06 Mil. DMK Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. DMK Pharmaceuticals's annualized EBITDA for the quarter that ended in Sep. 2023 was $-6.56 Mil. DMK Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.01.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for DMK Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of DMK Pharmaceuticals was 0.55. The lowest was -0.35. And the median was -0.13.
The historical data trend for DMK Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Mar13 | Mar14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.07 | -0.17 | -0.13 | -0.02 | -0.02 |
DMK Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.03 | -0.05 | -0.01 | -0.01 | -0.01 |
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
DMK Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.343 | + | 0) | / | -23.575 | |
= | -0.01 |
DMK Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.063 | + | 0) | / | -6.56 | |
= | -0.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.
DMK Pharmaceuticals (OTCPK:DMKPQ) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of DMK Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Dorbin John W. Jr. | officer: General Counsel | C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402 |
Seth Cohen | officer: CFO | C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018 |
Ebrahim Versi | director, officer: CEO | 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Jannine Versi | director | 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Vickie S Reed | director | TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037 |
David J. Marguglio | director | 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014 |
Carlo Dennis J Phd | director, 10 percent owner, officer: President/CEO | PO BOX 1176, RANCHO SANTA FE CA 92067 |
Ronald B. Moss | officer: Chief Medical Officer | 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130 |
David C. Benedicto | officer: Chief Financial Officer | 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Meera J. Desai | director | 1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Robert O Hopkins | officer: Chief Financial Officer | 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014 |
Karen K. Daniels | officer: Vice President of Operations | 11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130 |
Howard C Birndorf | director | C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Roshawn A. Blunt | director | 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130 |
Richard C Williams | director | 26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134 |
From GuruFocus
By sperokesalga sperokesalga • 05-25-2023
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 10-20-2023
By PRNewswire • 08-03-2023
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By PRNewswire • 06-26-2023
By Marketwired • 10-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.